Αποτελέσματα Αναζήτησης
Our study provides evidence for brexpiprazole and cariprazine as efficacious augmentation agents in TRD as well. Brexpiprazole, was FDA approved as an adjunctive treatment to oral antidepressants in MDD based on 3 trials which showed a significant reduction in depressive symptoms (Fava et al., 2016; Thase et al., 2015a; Thase et al., 2015b).
Treatment for Bipolar Disorder in Adults: A Systematic Review [Internet]. Show details
To date, the US Food and Drug Administration (FDA) has approved several drugs for the treatment of BD- D, including a combination of olan-zapine plus fluoxetine (OFC) (approved 2003), quetiapine (2008), lurasidone (2013), cariprazine (2019) and lumateperone (2021) (table 1).2 5 Although effective in clinical trials, these treatment options are o...
4 Αυγ 2022 · The current FDA-approved medications for BD-D include OFC, quetiapine, lurasidone, cariprazine and lumateperone, all of which come with clearly established short-term benefits but also significant long-term adverse effects. It is thus imperative to both investigate the long-term risk–benefit trade-offs and explore novel treatment approaches.
This drug review provides a comprehensive analysis of a novel antipsychotic called lumateperone, marketed as Caplyta. Lumateperone gained FDA approval in 2019 for treating schizophrenia and later, in 2021, for treating bipolar depression.
18 Ιουλ 2019 · One of the three FDA-approved medications (olanzapine-fluoxetine combination, quetiapine, and lurasidone) should be considered as the first-line treatment for bipolar depression.
28 Ιαν 2022 · With the FDA’s expanded indication, Caplyta (lumateperone) becomes just the second medication for both bipolar I and bipolar II depression. It is also the first approved for use in combination with lithium or valproate for bipolar II depression.
